Inborn errors of metabolism elicit unique challenges for therapy development
In recent years, major progress has been made in the development of gene therapies for rare diseases. However, research for…
All articles by Akosua Mireku
Akosua Mireku
@AkosuaMireku1
Akosua Mireku is a healthcare reporter for Pharmaceutical Technology. Akosua has a Bsc in medical physiology from the University of Manchester. She is particularly interested in topics in neuroscience, rare diseases, and global health equality
-
-
How to adapt to choppy waters in biotech ecosystem
As the US enters a new political era, experts predict that the pharmaceutical and clinical trials industry will have to…
-
US Border Protection warns pharma of risks with incorrect biologic importation
The incorrect transport of biological materials opens the US up to risk of infectious disease and biological threats, says Sean…
-
UAE’s clinical trials space matures with experience from Covid-19
The United Arab Emirates (UAE)’s clinical research landscape, is quickly developing with a regulatory framework coming into place over the…
-
Social media engagement boosts rare disease outreach
Social media has become an excellent tool for targeting specific patients for clinical trials, says Chris Adams, the CEO at…
-
Social media engagement boosts rare disease outreach
Social media has become an excellent tool for targeting specific patients for clinical trials, says Chris Adams, the CEO at…
-
Pharma companies must adapt to keep pace with AI developments, say experts
As artificial intelligence (AI) permeates clinical trial operations more than ever, workforces will have to adapt to the changing tides,…
-
ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction
A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at…
-
ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction
A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at…
-
Era of ADCs: Pharma companies innovate to stand out in a buzzing market
Antibody drug conjugates (ADCs) have taken over the cancer clinical research and dealmaking landscape, with new partnerships and agreements being…